NeoGenomics, Inc. (NEO) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
NEO Insider Trading Activity
NEO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $547,294 | 7 | 70 |
Sells | $112,682 | 3 | 30 |
Related Transactions
| Sherman Jeffrey Scott | Chief Financial Officer | 1 | $150,104 | 0 | $0 | $150,104 |
| Zook Anthony P. | Chief Executive Officer | 1 | $148,919 | 0 | $0 | $148,919 |
| Perez David Brian | director | 1 | $76,300 | 0 | $0 | $76,300 |
| TETRAULT LYNN A. | director | 1 | $56,974 | 0 | $0 | $56,974 |
| Stone Warren | Pres & Chief Operating Officer | 1 | $48,895 | 0 | $0 | $48,895 |
| Gunn Neil | director | 1 | $34,977 | 0 | $0 | $34,977 |
| KANOVSKY STEPHEN M | director | 1 | $31,124 | 0 | $0 | $31,124 |
| Olivo Alicia C | General Counsel | 0 | $0 | 3 | $112,682 | $-112,682 |
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Insider Activity of NeoGenomics, Inc.
Over the last 12 months, insiders at NeoGenomics, Inc. have bought $547,294 and sold $112,682 worth of NeoGenomics, Inc. stock.
On average, over the past 5 years, insiders at NeoGenomics, Inc. have bought $534,002 and sold $19.59M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Sherman Jeffrey Scott (Chief Financial Officer) — $150,104. Zook Anthony P. (Chief Executive Officer) — $148,919. Perez David Brian (director) — $76,300.
The last purchase of 5,700 shares for transaction amount of $48,895 was made by Stone Warren (Pres & Chief Operating Officer) on 2025‑05‑12.
List of Insider Buy and Sell Transactions, NeoGenomics, Inc.
| 2025-05-12 | Stone Warren | Pres & Chief Operating Officer | 5,700 0.0223% | $8.58 | $48,895 | -0.48% | ||
| 2025-05-09 | TETRAULT LYNN A. | director | 7,000 0.0275% | $8.14 | $56,974 | +2.52% | ||
| 2025-05-07 | KANOVSKY STEPHEN M | director | 4,000 0.0151% | $7.78 | $31,124 | +5.94% | ||
| 2025-05-06 | Zook Anthony P. | Chief Executive Officer | 18,900 0.0752% | $7.88 | $148,919 | +1.36% | ||
| 2025-05-05 | Gunn Neil | director | 4,510.31 0.0173% | $7.75 | $34,977 | +3.70% | ||
| 2025-05-05 | Perez David Brian | director | 10,000 0.0378% | $7.63 | $76,300 | +3.70% | ||
| 2025-05-02 | Sherman Jeffrey Scott | Chief Financial Officer | 20,000 0.0757% | $7.51 | $150,104 | +5.55% | ||
| 2024-11-15 | Sale | Olivo Alicia C | General Counsel | 5,175 0.0039% | $15.36 | $79,475 | -16.02% | |
| 2024-08-15 | Sale | Olivo Alicia C | General Counsel | 1,040 0.0008% | $16.05 | $16,695 | -13.06% | |
| 2024-05-15 | Sale | Olivo Alicia C | General Counsel | 1,049 0.0009% | $15.74 | $16,511 | -6.87% | |
| 2024-03-04 | Sale | TETRAULT LYNN A. | director | 6,112 0.0048% | $15.97 | $97,579 | -7.78% | |
| 2024-02-15 | Sale | Olivo Alicia C | General Counsel | 2,587 0.002% | $14.96 | $38,713 | +0.30% | |
| 2023-11-17 | Sale | Olivo Alicia C | General Counsel | 2,669 0.002% | $18.39 | $49,083 | -21.61% | |
| 2022-03-07 | Sale | Bonello William | Chief Financial Officer | 3,209 0.0026% | $18.29 | $58,693 | -43.84% | |
| 2021-12-21 | Sale | McKenzie Kathryn B | Chief Financial Officer | 1,846 0.0015% | $35.00 | $64,610 | -70.51% | |
| 2021-12-06 | Mallon Mark | Chief Executive Officer | 17,000 0.0137% | $30.63 | $520,710 | -67.38% | ||
| 2021-11-26 | Sale | Brown Douglas Matthew | Chief Strategy Officer | 33,334 0.0279% | $36.85 | $1.23M | -71.51% | |
| 2021-11-24 | Sale | Brown Douglas Matthew | Chief Strategy Officer | 33,333 0.0272% | $36.84 | $1.23M | -72.23% | |
| 2021-11-24 | Sale | Bonello William | President, Informatics | 25,000 0.0206% | $37.13 | $928,250 | -72.23% | |
| 2021-11-23 | Sale | Brown Douglas Matthew | Chief Strategy Officer | 33,333 0.0277% | $37.19 | $1.24M | -71.94% |
Insider Historical Profitability
| Sherman Jeffrey Scott | Chief Financial Officer | 158494 0.6158% | $1.26M | 1 | 0 | |
| Stone Warren | Pres & Chief Operating Officer | 108280 0.4207% | $861,908.80 | 1 | 0 | |
| KANOVSKY STEPHEN M | director | 40090 0.1558% | $319,116.40 | 1 | 0 | |
| Olivo Alicia C | General Counsel | 37129 0.1443% | $295,546.84 | 0 | 5 | |
| Zook Anthony P. | Chief Executive Officer | 18900 0.0734% | $150,444.00 | 1 | 0 | |
| Gunn Neil | director | 15846 0.0616% | $126,136.63 | 1 | 0 | |
| Perez David Brian | director | 10000 0.0389% | $79,600.00 | 1 | 0 | |
| TETRAULT LYNN A. | director | 7000 0.0272% | $55,720.00 | 3 | 3 | +1.25% |
| KINDERHOOK, LP | 10 percent owner | 4848334 18.8365% | $38.59M | 5 | 0 | +67.12% |
| VAN OORT DOUGLAS M | Chairman and CEO | 2422790 9.4129% | $19.29M | 10 | 8 | +14.16% |
| DENT MICHAEL T | director | 1384150 5.3776% | $11.02M | 0 | 11 | |
| JONES STEVEN C | director | 1000000 3.8852% | $7.96M | 0 | 49 | |
| CARDOZA GEORGE | President, Pharma Services | 176772 0.6868% | $1.41M | 2 | 12 | +53.16% |
| SHOVLIN ROBERT J. | President, Clinical Services | 150101 0.5832% | $1.19M | 1 | 11 | +4.86% |
| Weiss Lawrence Martin | Chief Medical Officer | 100521 0.3905% | $800,147.16 | 0 | 1 | |
| Bonello William | Chief Financial Officer | 98516 0.3827% | $784,187.36 | 0 | 7 | |
| Mallon Mark | Chief Executive Officer | 72736 0.2826% | $578,978.56 | 1 | 0 | <0.0001% |
| HIPP RAYMOND R | director | 66800 0.2595% | $531,728.00 | 0 | 6 | |
| ALBITAR MAHER | Chief Medical Officer | 60692 0.2358% | $483,108.32 | 1 | 5 | +25.36% |
| Pedulla Denise E | General Counsel | 56726 0.2204% | $451,538.96 | 0 | 1 | |
| CROWTHER BRUCE K | director | 49564 0.1926% | $394,529.44 | 1 | 3 | <0.0001% |
| HANNAH ALISON L. | director | 38782 0.1507% | $308,704.72 | 2 | 0 | +9.16% |
| Johnson Kevin C | director | 30983 0.1204% | $246,624.68 | 3 | 4 | +42.62% |
| BALLIET JENNIFER | VP and Chief Culture Officer | 24980 0.0971% | $198,840.80 | 0 | 12 | |
| BRODIE STEVEN G. | President, Pharma Services | 15953 0.062% | $126,985.88 | 0 | 2 | |
| McKenzie Kathryn B | Chief Financial Officer | 11689 0.0454% | $93,044.44 | 0 | 2 | |
| Brown Douglas Matthew | Chief Strategy Officer | 11644 0.0452% | $92,686.24 | 0 | 3 | |
| GASPARINI ROBERT P | Chief Science Officer | 8439 0.0328% | $67,174.44 | 0 | 14 | |
| ROSS STEVEN A | CIO | 4500 0.0175% | $35,820.00 | 0 | 6 | |
| GENERAL ELECTRIC CO | 0 0% | $0 | 0 | 2 | ||
| SMITS MARK W | Chief Commercial Officer | 0 0% | $0 | 0 | 1 | |
| HOREL ROBERT H. | Vice President andGM PathLogic | 0 0% | $0 | 0 | 2 |
NEO Institutional Investors: Active Positions
| Increased Positions | 95 | +27.86% | 5M | +3.98% |
| Decreased Positions | 146 | -42.82% | 10M | -8.35% |
| New Positions | 23 | New | 614,742 | New |
| Sold Out Positions | 42 | Sold Out | 2M | Sold Out |
| Total Postitions | 290 | -14.96% | 118M | -4.37% |
NEO Ownership Change vs Market
Institutional Investor Ownership
| Blackrock, Inc. | $152,956.00 | 15.4% | 19.86M | -379,241 | -1.87% | 2025-03-31 |
| Vanguard Group Inc | $109,647.00 | 11.04% | 14.24M | +195,793 | +1.39% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $50,266.00 | 5.06% | 6.53M | -13,289 | -0.2% | 2024-12-31 |
| Janus Henderson Group Plc | $47,471.00 | 4.78% | 6.17M | -438,117 | -6.63% | 2024-12-31 |
| State Street Corp | $40,028.00 | 4.03% | 5.2M | +239,905 | +4.84% | 2024-12-31 |
| Greenhouse Funds Lllp | $36,205.00 | 3.65% | 4.7M | +237,491 | +5.32% | 2024-12-31 |
| Brown Advisory Inc | $29,814.00 | 3% | 3.87M | -2M | -37.1% | 2025-03-31 |
| Macquarie Group Ltd | $29,354.00 | 2.96% | 3.81M | -12,389 | -0.32% | 2024-12-31 |
| Schroder Investment Management Group | $29,262.00 | 2.95% | 3.8M | -419,612 | -9.94% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $26,464.00 | 2.66% | 3.44M | +78,211 | +2.33% | 2024-12-31 |